drugset / Trial / NCT05075070
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected
Phase 4
Unknown
400 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabZhejiang Provincial Center for Disease Control and Prevention · collab
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
Timeline
- Start
- 2021-10-08
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Publications
- Zhang H, Deng X, Dai R, Fu J, Ding L, Hu X, Sun P, Shu R, Chen L, Xu X. Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study. J Virol. 2025 Sep 23;99(9):e0068825. doi: 10.1128/jvi.00688-25. Epub 2025 Aug 21.
- Wang Y, Li J, Zhang W, Liu S, Miao L, Li Z, Fu A, Bao J, Huang L, Zheng L, Li E, Zhang Y, Yu J. Extending the dosing interval of COVID-19 vaccination leads to higher rates of seroconversion in people living with HIV. Front Immunol. 2023 Mar 2;14:1152695. doi: 10.3389/fimmu.2023.1152695. eCollection 2023.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |